Published in Am J Med Genet A on January 01, 2010
The RASopathies. Annu Rev Genomics Hum Genet (2013) 2.06
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet (2010) 2.03
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ (2012) 1.27
Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol (2012) 1.25
Novel allosteric sites on Ras for lead generation. PLoS One (2011) 1.20
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation. J Clin Invest (2013) 1.11
Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. Dis Model Mech (2012) 0.96
The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A (2012) 0.91
New Genetic Insights into Congenital Heart Disease. J Clin Exp Cardiolog (2012) 0.89
Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development. Dev Biol (2012) 0.83
Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis. Clin Genet (2012) 0.83
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet (2013) 0.81
BRAF gene: From human cancers to developmental syndromes. Saudi J Biol Sci (2014) 0.81
K-Ras protein as a drug target. J Mol Med (Berl) (2016) 0.80
Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol (2013) 0.78
RASOnD-a comprehensive resource and search tool for RAS superfamily oncogenes from various species. BMC Genomics (2011) 0.78
In vivo severity ranking of Ras pathway mutations associated with developmental disorders. Proc Natl Acad Sci U S A (2017) 0.77
Craniofacial and dental development in Costello syndrome. Am J Med Genet A (2014) 0.76
Shifting the paradigm for autism treatments. Neurotherapeutics (2010) 0.76
From the transcription of genes involved in ectodermal dysplasias to the understanding of associated dental anomalies. Mol Syndromol (2012) 0.76
Loss of neurofibromin Ras-GAP activity enhances the formation of cardiac blood islands in murine embryos. Elife (2015) 0.75
Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas. J Neurooncol (2017) 0.75
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev (2009) 5.53
Causal protein-signaling networks derived from multiparameter single-cell data. Science (2005) 34.28
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med (2006) 9.50
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Computational solutions to large-scale data management and analysis. Nat Rev Genet (2010) 6.58
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 6.24
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol (2009) 5.86
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol (2011) 5.46
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity (2012) 5.26
Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods (2006) 5.25
Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat Genet (2004) 5.19
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci (2010) 5.12
Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci (2004) 4.99
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev (2003) 4.89
Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA (2004) 4.88
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol (2013) 4.88
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet (2012) 4.51
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A (2003) 4.45
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol (2004) 4.40
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 4.32
The involvement of the anterior cingulate cortex in remote contextual fear memory. Science (2004) 4.29
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med (2007) 4.25
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Mathematical models of protein kinase signal transduction. Mol Cell (2002) 4.08
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med (2012) 4.04
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96
Mutations in embryonic myosin heavy chain (MYH3) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. Nat Genet (2006) 3.94
New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst (2006) 3.90
The fragile-X premutation: a maturing perspective. Am J Hum Genet (2004) 3.89
The FMR1 premutation and reproduction. Fertil Steril (2006) 3.85
Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet (2010) 3.82
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol (2003) 3.75
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet (2006) 3.69
Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med (2006) 3.66
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol (2012) 3.65
PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 3.61
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Neuronal competition and selection during memory formation. Science (2007) 3.48
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46